Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 11/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 11/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.44 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 9/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918210 | 0.83 | AKT1 (0.43) | ROCK1CDC42BPBROCK2CDC42BPAAKT1 | |
| SCHEMBL4725770 | 0.83 | AKT1 (0.43) | ROCK1CDC42BPBROCK2CDC42BPAAKT1 | |
| SCHEMBL4781944 | 0.79 | AKT1 (0.62) | AKT1 | |
| SCHEMBL4782326 | 0.73 | AKT1 (0.60) | AKT1 | |
| SCHEMBL4778683 | 0.71 | AKT1 (0.57) | AKT1 | |
| SCHEMBL4910957 | 0.70 | AKT1 (0.67) | AKT1 | |
| SCHEMBL4725273 | 0.69 | AKT1 (0.60) | AKT1 | |
| SCHEMBL4776709 | 0.69 | AKT1 (0.59) | AKT1 | |
| SCHEMBL4782370 | 0.69 | AKT1 (0.54) | AKT1 | |
| SCHEMBL4920000 | 0.67 | AKT2 (0.69) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | ROCK1 215/4885CDC42BPB 2238/4885ROCK2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.